ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center trial in the US and Europe to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS27 study will compare four dosing regimens and determine the minimum effective dose of alicaforsen enema in UC patients over six weeks as compared to a placebo enema. (The probability of receiving active formulation is 4:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ionis Pharmaceuticals, Inc.
• Treatments: Alicaforsen

Criteria

Inclusion Criteria

Patients must meet the following criteria at screening to be eligible for enrollment:

• Age greater than or equal to 18 years

• Diagnosis of left-sided ulcerative colitis of at least 6 months duration

• Current left-sided flare, defined as activity in the colon 5-50 cm from the anal verge, extending at least 15 cm proximal to the anal verge and confirmed by endoscopic evaluation within 14 days of baseline visit.

• Baseline DAI score of 4-10 including abnormal endoscopic score

• On at least one or more of the following treatments for ulcerative colitis prior to baseline visit:

1. Stable background oral mesalamine therapy for greater than or equal to 30 days, and/or

2. Stable background mercaptopurine for greater than or equal to 60 days prior to baseline, and/or

3. Stable azathiprine therapy for greater than or equal to 60 days prior to baseline

• Written informed consent prior to performing screening evaluations.

Exclusion Criteria

Patients who meet any of the following criteria at screening are not eligible for enrollment:

• Bowel stricture, toxic megacolon, colonic dysplasia, adenoma or carcinoma

• Patients with pancolitis

• Uncontrolled hematologic, renal, hepatic, metabolic, psychiatric, CNS, pulmonary or cardiovascular disease, or sufficient level of disease that could interfere with the patient's ability to comply with protocol participation

• Enteric pathogens or presence of Clostridium difficile toxin in stool

• History of colon resection

• Major surgical procedure within one month of baseline visit

• Steroid or mesalamine enema within 14 days of baseline visit

• Systemic steroids (including ACTH) within 30 days of baseline visit

• Tumor necrosis factor-alpha (TNF-α) inhibitor treatment within 90 days of baseline visit

• Non-steroidal anti-inflammatory agents (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors, within 14 days of baseline visit

• Methotrexate, cyclosporin or thalidomide within 90 days of baseline visit

• Any active infection currently requiring treatment

• Malignancy within 5 years except for squamous cell or basal cell cancers of the skin

• Current infectious, ischemic, or immunological disease with gastrointestinal involvement

• ISIS 2302 treatment within 12 months of baseline visit

• Treatment with an investigational or off-label drug within 90 days of screening or currently in long-term follow up for another investigational treatment protocol